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Abstract
Objective—The conditionally replicative adenovirus Ad5/3-Δ24 has a type-3 knob incorporated
into the type-5 fiber that facilitates enhanced ovarian cancer infectivity. Preclinical studies have
shown that Ad5/3-Δ24 achieves significant oncolysis and antitumor activity in ovarian cancer
models. The purpose of this study was to evaluate in a Phase I trial the feasibility and safety of
intraperitoneal (IP) Ad5/3-Δ24 in recurrent ovarian cancer patients.
Methods—Eligible patients were treated with IP Ad5/3-Δ24 for 3 consecutive days in one of
three dose cohorts ranging 1 × 1010–1 × 1012 vp. Toxicity was assessed utilizing CTC grading and
efficacy with RECIST. Ascites, serum, and other samples were obtained to evaluate gene transfer,
generation of wildtype virus, viral shedding, and antibody response.
Results—Nine of 10 patients completed treatment per protocol. A total of 15 vector-related
adverse events were experienced in 5 patients. These events included fever or chills, nausea,
fatigue, and myalgia. All were grade 1–2 in nature, transient, and medically managed. Of the 8
treated patients evaluable for response, six patients had stable disease and 2 patients had
progressive disease. Three patients had decreased CA-125 from pretreatment levels one month
© 2013 Elsevier Inc. All rights reserved.
Corresponding Author: Ronald D. Alvarez, M.D., University of Alabama at Birmingham, Division of Gynecologic Oncology, 176F
Rm 10250, 619 19th Street South, Birmingham, Alabama 35249, rdalvarez@uab.edu, phone: (205) 934-4986, fax: (205) 975-6174.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Conflict of Interest Disclosure: The authors declare that there are no conflicts of interest.
NIH Public Access
Author Manuscript
Gynecol Oncol. Author manuscript; available in PMC 2014 September 01.
Published in final edited form as:













after treatment. Ancillary biologic studies indicated Ad5/3-Δ24 replication in patients in the
higher dose cohorts. All patients experienced an anti-adenoviral neutralizing antibody effect.
Conclusions—This study suggests the feasibility and safety of a serotype chimeric infectivity-
enhanced CRAd, Ad5/3-Δ24, as a potential therapeutic option for recurrent ovarian cancer
patients.
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Introduction
Nearly 22,000 ovarian cancer patients are diagnosed in the U.S. annually (1). With no
effective screening, symptoms are often nonspecific and the majority of affected patients
present with advanced disease. Though advances in surgical cytoreduction and cytotoxic
chemotherapy have improved median survival, most patients develop chemotherapy
resistance and ultimately succumb to their disease (2–5). Thus, there is a need for novel
therapeutic approaches for this disease.
To address this need, several gene therapy strategies have been evaluated for ovarian cancer
treatment (6–7). Virotherapy utilizing serotype-5 conditionally-replicative adenoviruses
(CRAds) has been the basis for one such approach. This strategy takes advantage of the
propensity of serotype-5 CRAds to infect cancer cells, replicate selectively within these
cells, and induce cell death via oncolysis. The prototype CRAd, ONYX-015, was a
serotype-5 adenovirus modified to conditionally replicate in cells with p53 deficiencies.
ONYX-015 has been evaluated in early phase trials, demonstrating feasibility and safety
when administered intraperitoneally (IP) to patients with recurrent ovarian cancer (8–9).
However, the clinical utility of serotype-5 CRAds, such as ONYX-015, in ovarian cancer
may be hampered by their inability to effectively infect ovarian cancer cells due to the
paucity of the primary serotype-5 adenoviral cell surface receptor, the coxsackie-adenovirus
receptor (CAR), on their surface (10–11).
We have developed several novel approaches designed to enhance the infectivity of
serotype-5 adenoviruses utilizing various CAR-independent pathways. In one of these
approaches, we have modified a serotype-5 adenovirus by replacing its knob with a
serotype-3 knob onto its fiber (Supplemental Figure 1). This alters the tropism of these 5/3
serotype-chimeric adenoviruses towards serotype-3 adenoviral receptors, which are more
abundantly expressed by ovarian cancer cells (12). Our preclinical studies have
demonstrated a reporter-gene-expressing Ad5/3 chimeric adenoviral vector to display higher
transgene expression compared to unmodified reporter-gene-expressing adenoviral vectors
in established and primary ovarian cancer cells. (13)
This 5/3 serotype-chimeric fiber knob modification has been incorporated into the CRAd,
Ad5/3-Δ24 (14) (Supplemental Figure 1). Ad5/3-Δ24 contains a 24-base-pair deletion in the
E1A constant region 2 (CR2) allowing for selective replication within Rb-p16-deficient
tumor cells, a deficiency observed in most ovarian cancer cells (15–16). The replicative and
oncolytic potency of Ad5/3-Δ24 has been confirmed in vitro in various established and
primary ovarian cancer cell lines (14). Additional preclinical studies have established the
antitumor activity of Ad5/3-Δ24 in in vivo ovarian cancer models (14). Biodistribution and
safety studies conducted in Syrian hamsters demonstrated that IP-administered Ad5/3-Δ24
remained predominantly confined to the abdominal cavity and was well-tolerated. (17) Thus,
Ad5/3-A24 seemed suited to be evaluated in early phase clinical trials in the context of
gynecologic cancers.
Kim et al. Page 2













The primary purpose of this study was to determine the maximum tolerated dose (MTD) and
toxicities associated with IP administration of Ad5/3-Δ24 in patients with selected recurrent




This was a standard 3+3 dose-escalating phase I trial evaluating IP Ad5/3-Δ24 in cohorts of
eligible patients. The study was approved by both the Institutional Review Board (IRB) and
the Institutional Biosafety Committee (IBC) of the University of Alabama at Birmingham
(UAB). The study was also approved by the NIH Recombinant DNA Advisory Committee
and the US Food and Drug Administration (FDA).
Eligibility
Eligible patients included women 19 years or older with recurrent epithelial ovarian, primary
peritoneal, fallopian tube, or endometrial cancer. Patients must have been previously treated
with standard surgical procedures and adjuvant therapies. Patients were required to have
adequate organ function as defined by a white blood cell count >3000µL, granulocyte count
>1,500µL, platelets >100,000, creatinine clearance >80mg/dL, creatinine <2.0, aspartate
aminotransferase or alanine aminotransferase <2.5x the upper limit of normal reference
range, bilirubin <2.0, and a prothrombin time/international normalized ratio or partial
thromboplastin time (PT/INR/PTT) <1.5x the upper limit of normal reference range. Patients
were also required to have an oxygen saturation >92% on room air, a Gynecologic Oncology
Group (GOG) performance status of 0–2 and a life expectancy >3 months. Those patients
found to have borderline, germ cell or sex cord/stromal tumors were excluded. Patients with
recurrence solely located beyond the abdominal cavity were excluded. Patients with active
heart disease (characterized by angina, unstable arrhythmia, CHF, a known EF < 5%, or
pulmonary hypertension), active or chronic debilitating pulmonary disease (i.e., active
pneumonia, severe COPD, pulmonary edema, O2 saturation <92%), or coagulopathies (i.e.,
bleeding disorders, on therapeutic anti-coagulants) were excluded. All patients were
required to sign informed consent.
Ad5/3-Δ24
Ad5/3-Δ24 is a serotype-chimeric, infectivity-enhanced adenoviral vector developed in the
Gene Therapy Center at UAB (22) (Figure 1). The replication-competent Ad5-Δ24 mutant
adenovirus was provided by J. Fueyo (MD Anderson Cancer Center, Houston TX). This
virus contains a 24-nucleotide deletion from bp 923–946 corresponding to the amino acid
sequence L122TCHEAGF129 of the E1A protein necessary for Rb protein binding (16). A
fiber shuttle vector pNEB.PK.F5/3 containing the Ad5 tail and shaft with Ad3 knob was
digested with Pac I and KpnI, followed by cotransformation into E.coli for homologous
recombination with a SwaI-linearized rescue plasmid containing an E1-deletion. This
resulted in a plasmid with the E1-deleted Ad5 genome containing the chimeric fiber domain
(pTU.5/3) (18). In order to create Ad5/3-Δ24, a shuttle vector containing a 24-bp deletion in
the CR2 region of E1A (pShuttleΔ24) was used (19). pShuttleΔ24 was linearized with PacI/
PmeI and cotransfected into 911 cells with PacI-linearized pTU.5/3 to rescue the Ad5/3-
Δ24. Propagation was performed in A549 cells. Ad5/3-Δ24 was formulated in 20mM Tris,
25mM NaCl, 2.5% (w/v) Glycerol, pH 8.0 (GST). Each vial contained 1mL fill volume with
4.83 ×1011 viral particles(vp)/mL and was provided in sterile, single use containers. Ad5/3-
Δ24 was manufactured with support from the NCI RAID Program at the Biopharmaceutical
Development Program/SAIC at NCI-Frederick.
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Treatment Plan and Dose Cohorts
Pretreatment evaluation included a history and physical examination, toxicity grading,
performance status assignment, laboratory assessment (CBC with differential, chemistry
profile including renal and liver function tests, PT/PTT/INR, CA-125, and anti-adenovirus
neutralizing antibody titer), an abdominal-pelvic CT with tumor measurements (in two
dimensions, if possible), and O2 saturation determination. Eligible patients who completed
pretreatment evaluation were enrolled onto study and had an IP Quinton Curl, 22.4-inch,
double-cuffed, Tenckhoff catheter (Tyco Healthcare) placed by an interventional radiologist
at least one week prior to use.
Patients were assigned into one of three Ad5/3-Δ24 dose cohorts ranging from 1×1010 vp/
dose–1×1012 vp/dose (Supplemental Table 1). Assigned doses were administrated IP daily
for three consecutive days. On days 1–4, 11, 18, and 29, a history and physical, performance
status, toxicity grading, CBC, and chemistry panel were obtained on all patients. CA-125
and an abdominal-pelvic CT scan were repeated on day 29.
Peritoneal aspirates, serum, saliva, and urine specimens were obtained immediately
preceding Ad5/3-Δ24 administration and subsequently on days 3, 8, 15, and 29 for ancillary
biologic studies. All samples were processed and de-identified prior to these studies.
Evaluation of Clinical Toxicity
Clinical toxicity was assessed on the specified days and graded with NCI Common Toxicity
Criteria (CTC) Version 1.0. Dose limiting toxicity (DLT) was defined as any vector-related,
grade 3, non-hematologic toxicity, or a hematologic toxicity as defined by any admission for
neutropenic fever, absolute neutrophil count <500 for >5 days, or platelet count <20,000.
The MTD was defined as the dose exceeded by the dose at which at least two patients
experienced DLT.
Evaluation of Clinical Efficacy
Though not a primary objective of this study, clinical efficacy was assessed utilizing
RECIST criteria, comparing pre- and post-treatment CT findings (20). Measurable disease
was defined as at least one lesion >1cm that could be measured in one dimension. In each
patient, up to five lesions/organ or ten lesions total were identified as target lesions.
Complete response (CR) was defined as disappearance of all target lesions. Partial response
(PR) was defined as >30% decrease in the sum total recorded dimensions of a patient’s
target lesions. Progressive disease (PD) was deemed as >20% increase in the sum total
recorded dimensions of a patient’s target lesions. Any condition that did not qualify for PR,
CR, or PD was deemed stable disease (SD). In addition, pre- and post-treatment CA-125
values were compared. Normalization of an initially elevated CA-125 was required in
enrolled ovarian cancer patients if a RECIST-defined CR was noted.
Assessment of Cellular Infection, Viral Replication and Generation of WildType
Adenovirus in Ascites
Total DNA from cellular material obtained from ascites samples was isolated using a
QIAamp DNA MiniKit (QIAGEN) according to manufacturer protocol. Duplexing
quantitative PCR was employed to evaluate Ad5/3-Δ24 infection. Ad5/3-Δ24 genome
copies present in each peritoneal aspirate sample were determined by Real-Time PCR
(LightCycler system, Roche Molecular Biochemicals, Indianapolis, IN) with the Ad5 hexon
gene-specific forward primer 5’-TAC-GCA-CGA-CGT-GAC-CAC-A-3’, reverse primer 5’-
ATC-CTC-ACG-GTC-CAC-AGG-G-3’, and probe 6-FAM-ACC-GGT-CCC-AGC-GTT-
TGA-CGC-BHQ-1 and normalized to the concentration of genomic DNA by amplifying the
human β-actin housekeeping gene with forward primer, reverse primer and probe: 5’-CCA-
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GCA-GAT-GTG-GAT-CAG-CA-3’, 5’-CTA-GAA-GCA-TTT-GCG-GTG-GAC-3’ and 6-
HEX-AGG-AGT-ATG-ACG-AGT-CCG-GCC-CCT-C-BHQ-1, respectively.
Ad5/3-Δ24 replication was evaluated by comparison of E1A copies as detected in the
specimens of total RNA, isolated from ascites samples using the QIAamp RNeasy MiniKit
(QIAGEN, Valencia, CA) and used as a template for quantitative reverse transcription PCR
(RT-PCR). Duplexing RT-PCR was carried out using the TaqMan one step PCR master mix
supplemented with RT enzyme (Applied Biosystems) and primers and probes specific for
the E1A target gene (forward primer 5’-AAC-CAG-TTG-CCG-TGA-GAG-TTG-3’, reverse
primer 5’-CTC-GTT-AAG-CAA-GTC-CTC-GAT-ACA-3’, probe 6-FAM-CAC-AGC-
CTG-GCG-ACG-CCC-A-BHQ-1) and the human β-actin housekeeping gene (above). Data
was analyzed with LightCycler 480 1.5.0 SP1 software and the resultant E1A copies were
normalized to the amount of human β-actin detected in the same sample to allow for
comparison between patients and at different time points.
Generation of wildtype adenovirus was examined with LightCycler methodology for
amplification of the Ad5 E1 genome without Δ24 deletion by forward and reverse primers:
5’-TGC-CAA-ACC-TTG-TAC-CGG-A-3’ and 5’-CGT-CGT-CAC-TGG-GTG-GAA-A-3’,
and probe 6-FAM-ATC-GAT-CTT-ACC-TGC-CAC-GAG-GCT-GG-BHQ-1.
Assessment for Ad5/3-Δ24 Viral Shedding
Total DNA from Ad5/3-Δ24-treated.patients’ blood, saliva, and urine specimens was
isolated using the QIAamp DNA MiniKit (QIAGEN) according to manufacturer protocol.
Urine specimens were initially concentrated with Millipore Amicon Ultra-4 Centrifugal
Filter Units and then used to isolate viral DNA with the QIAampMinElute Virus Spin Kit
(QIAGEN), according to manufacturer instructions. The DNA samples isolated from blood,
saliva, and urine were used to detect the adenovirus genome by Real-Time PCR using the
Ad5 hexon gene-specific forward primer 5’-TAC-GCA-CGA-CGT-GAC-CAC-A-3’,
reverse primer 5’-ATC-CTC-ACG-GTC-CAC-AGG G-3’, and probe 6-FAM-ACC-GGT-
CCC-AGC-GTT-TGA-CGC-BHQ-1.
Evaluation of an Anti-Adenoviral Neutralizing Antibody Response
To evaluate for an anti-adenoviral neutralizing antibody response after treatment, a
nonreplicative, luciferase-expressing virus, Ad5/3Luc1 was neutralized by either serum or
ascites from Ad5/3-Δ24-treated patients before infection of SKOV3.ip1 cells. SKOV3.ip1
cells were plated into 96-well plates (10,000 per well) and grown overnight prior to
infection. A 1:50 dilution of serum or ascites from each time point specimen was prepared in
1.3 ml of Opti-MEM media containing Ad5/3Luc1 and incubated for 30 minutes at room
temperature before addition to triplicate wells at 100 plaque-forming units per cell. This
infection proceeded for 48 hours and Ad5/3Luc1 transduction efficacy was determined by
luciferase assay. The luciferase assay was carried out using a luciferase assay system
(Promega) on an Orion microplate luminometer (Berthold) reading Culturplate-96 wells
(Research Parkway) according to manufacturer protocols.
Results
Patient Demographics and Treatment
From June 2010–December 2011, 10 patients met eligibility criteria and were enrolled in the
study. One patient experienced a complication related to IP catheter placement, and did not
receive treatment. Table 1 summarizes patient demographics. All other nine patients
completed Ad5/3-Δ24 treatment according to protocol without dose interruptions.
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Toxicity Associated with Intraperitoneal Administration of Ad5/3-Δ24
As noted, one patient had a complication related to the placement of her IP catheter and was
not treated per protocol. Briefly, she developed sepsis the day after IP catheter placement
from an unrecognized bowel injury, presumably encountered at the time of her IP catheter
placement. In spite of catheter removal, administration of antibiotics, and aggressive
resuscitation, her clinical course rapidly deteriorated and she expired 2 days after IP catheter
insertion. Another patient had a grade 1 IP catheter-associated infection prior to Ad5/3-Δ24
administration that appropriately responded to antibiotics.
Table 2 summarizes all 136 reportable clinical and laboratory adverse events noted in the
nine patients treated with Ad5/3-Δ24. A serious adverse event was noted in only one Ad5/3-
Δ24 treated patient. This patient, in the lowest dose cohort, completed Ad5/3-Δ24 therapy
with acute clinical adverse events that were only grade 1/2 in nature, attributed to her
underlying disease. Approximately 3 weeks later, prior to her study-specified exit
examination on day 29, she developed progressive weakness and bowel dysfunction,
aspirated and rapidly developed respiratory and cardiovascular compromise, requiring
intensive care supportive measures. These symptoms were attributed to her underlying
disease. Supportive care was eventually withdrawn after family consultation and she expired
soon thereafter.
Of the 136 clinical adverse events noted, 15 were classified as attributable to Ad5/3-Δ24
treatment. These vector-attributable adverse events occurred in a total of five patients; three
of the patients were in the lowest dose cohort and two were in the highest dose cohort. These
events all grade 1–2 and included: fever/chills (8), nausea (3), fatigue (2), and myalgia (2).
All events were transient and managed medically. There were no grade 3/4 clinical DLTs
attributable to Ad5/3-Δ24. There were no Ad5/3-Δ24-associated laboratory toxicities. The
MTD of Ad5/3-Δ24 was not identified.
Clinical Efficacy
Antitumor activity was assessed approximately one month after IP Ad5/3-Δ24 treatment by
utilizing RECIST criteria to compare pre- and post-treatment abdominal-pelvic CT
examinations, and by comparing pre- and post-treatment CA-125 levels (Table 3). Of the
eight Ad5/3-Δ24-treated patients evaluable for response by RECIST criteria, six (75%)
demonstrated SD while two (25%) experienced PD. Three (37.5%) had a decrease in their
CA-125 levels and five (62.5%) had an increase in CA-125. The three patients who had a
decrease in CA-125 levels all had RECIST-defined SD. All but one of these eight patients
went on to receive other therapies immediately. One patient who had stable disease and a
decrease in her CA125 at the one month follow-up examination elected to not receive
additional therapy; she was subsequently noted to have progressive disease 4 months after
her initial treatment with Ad5/3-Δ24 and was treated with another experimental therapeutic
approximately 6 months after treatment with Ad5/3-Δ24. The patient who experienced a
serious adverse event related to respiratory/cardiac compromise was declared to have PD by
virtue of clinical deterioration prior to her exit evaluation; she did not have a post-treatment
CA-125.
Ancillary Biologic Studies
Various tissue samples were obtained prior to and at several time points after Ad5/3-Δ24
administration to assess for gene expression, viral shedding, generation of wildtype virus,
and generation of an anti-adenovirus neutralizing antibody response. Figure 2 illustrates the
detection of Ad5/3-Δ24 in ascites samples. There appeared to be a direct correlation
between detectable Ad5/3-Δ24 genome copies and Ad5/3-Δ24 dose; detectable levels of
Ad5/3-Δ24 vector were found in the peritoneal lavage samples obtained from most patients
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in the intermediate (1 × 1011 vp/dose) and highest dose (1× 1012 vp/dose) cohorts on days 3
and 8 following treatment.
To evaluate the levels of Ad5/3-Δ24 replication, total mRNA isolated from each patient’s
ascites sample was used to detect the early viral E1A gene message by real time PCR
following reverse transcription. The detected levels of E1A mRNA (Figure 3) indicated
early viral gene expression in infected cells, suggesting active Ad5/3-Δ24 replication in all
patients from intermediate and highest dose cohorts on day 3 and 8 post-administration
while persisting until day 15 in patients 2−1, 3−1, and 3−3 and through day 29 in patients
3−2 and 3−3. The highest levels of adenovirus replication were seen on day 3 of patients in
the highest dose cohort (Figure 3), which is consistent with significantly increased number
of Ad5/3-Δ24 genome copies detected in these patient’s ascites (Figure 2).
Viral shedding studies (data not shown) determined that the adenoviral genomic DNA levels
were significantly elevated (>50 copies) in specimens from several patients including that
from the blood of patient 3−3 (day 3), saliva of patient 2−1 (day 15), and urine of patients
3−1 (day 15 and 29) and 3−2 (day 3). Viral shedding was noted more frequently in patients
in the intermediate and highest dose cohorts.
No emergence of wildtype adenovirus was revealed in any ascites samples (data not shown).
However, a significant level of adenoviral DNA was detected in the pre-treatment ascites
specimen from patient 1−1 (Figure 2).
A neutralizing anti-adenoviral antibody response was determined by blocking adenoviral
gene transfer in the presence of serum or ascites samples collected from patients before and
after Ad5/3-Δ24 administration. Preexisting immunity against adenovirus were noted on day
0 in the serum of patient 1−1 and the ascites of patients 1−1 through 2−3 (low and
intermediate dose cohorts) (Supplemental Figure 2). A marked increase in neutralizing
antibody responses, which significantly limited adenoviral gene transfer efficacy in this
assay, was noted in most serum and ascites specimens collected from patients on day 8, 15,
and 29 as compared to day 0 and 3.
Discussion
Various tropism alterations to enhance the cellular infectivity of adenoviral based gene
therapeutics have been accomplished. This study reports on the safety and potential efficacy
of the novel infectivity-enhanced, serotype-chimeric adenovirus Ad5/3-Δ24 in patients with
recurrent ovarian and select other gynecologic cancers. Incorporation of the serotype-3 knob
onto the serotype-5 fiber in this CRAd enhances infectivity and improves oncolysis in
ovarian cancer models (12–14). In this study, we were able to safely administer Ad5/3-Δ24
IP daily for three consecutive days at dosages up to 1×1012 vp/dose.
The clinical toxicities attributable to Ad5/3-Δ24 were manageable grade 1–2 constitutional
or pain symptoms. Attributable toxicities were scattered between the lowest and highest
cohorts and there did not appear to be a relationship between adverse events and Ad5/3-Δ24
dose. No Ad5/3-Δ24-specific laboratory abnormalities were noted; there were no grade 3/4
clinical or laboratory DLT directly attributable to Ad5/3-Δ24. Manufacturing constraints did
not allow for Ad5/3-Δ24 cohorts at higher dosages; thus, the MTD of Ad5/3-Δ24 was not
identified in this trial.
Most other adverse events experienced by Ad5/3-Δ24-treated patients were attributable to
their underlying disease. Of note, one patient enrolled on the study experienced a serious
bowel perforation related to IP catheter placement and did not receive treatment. Only one
other patient among over 60 patients treated in a series of four other phase I gene therapy
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trials of ours has experienced a bowel perforation (21–24). In that instance, the bowel injury
was immediately recognized and the IP catheter immediately removed. She recovered
uneventfully with the administration of intravenous antibiotics.
Though this trial was not primarily designed to determine clinical efficacy, six patients
(75%) had RECIST-defined SD one month after treatment and three patients (37.5%) had a
decrease in CA-125. All three patients who had a decrease in CA-125 had RECIST-defined
SD one month after treatment. All but one treated study patient went on to receive different
treatment for their disease right after the one-month follow-up evaluation. The one patient
who was observed was noted to have progressive disease 4 months after Ad5/3-Δ24
treatment. The true clinical efficacy of Ad5/3-Δ24 will need to be assessed in phase II
studies evaluating expanded cycles of Ad5/3-Δ24.
These results mimic those of other trials evaluating novel infectivity-enhanced CRAds in the
context of ovarian cancer. Koski et al. reported their phase I study evaluating the safety and
potential efficacy of a similar serotype-chimeric infectivity-enhanced CRAd (25). In this
trial, 21 patients with a variety of solid tumors were treated with a single intratumoral or
intravenous administration of up to 4×1011 vp of an Ad5/3-Δ24-modified CRAd expressing
GMCSF. Low-dose cyclophosphamide was also administered to reduce regulatory T-cells.
Grade 1–2 flu-like symptoms, injection site discomfort and abdominal pain were the most
common clinical effects. Four patients with ovarian cancer were included in this trial; one
was noted to have RECIST-defined SD and one other patient had a minor CA-125 response.
Our prior phase I trial investigated the safety, potential antitumor effect, and biologic
activity of the infectivity-enhanced CRAd, Ad5-Δ24-RGD, in patients with recurrent
selected gynecologic cancers (23). This Ad5-Δ24-based CRAd incorporated an Arg-Gly-
Asp (RGD) sequence in the HI loop of the serotype-5 fiber knob, redirecting viral tropism
towards ανβ-integrins, abundantly expressed on ovarian cancer cell surfaces (10, 11).
Preclinical studies demonstrated that this RGD modification enhanced the viral infectivity
and antitumor activity of Ad5-Δ24-RGD in various ovarian cancer models (26–27). In a
phase I trial, 21 patients with recurrent selected gynecologic cancers were treated IP with
Ad5-Δ24-RGD at dosages of up to 1×1012 vp/d daily for three days (23). Toxicities were
limited to grades 1/2 fever, fatigue or pain. Fifteen patients (71%) were noted to have SD
and seven patients (33%) were noted to have a decrease in CA-125. Similar clinical efficacy
and toxicity were noted in a separate phase I trial investigating the RGD-modified non-
replicative suicide gene-based serotype-5 adenovirus, Ad5.SSTR/TK.RGD (24).
Ancillary studies demonstrated a consistent dose-related increase in detectable Ad5/3-Δ24
vector and its replication in ascites samples with the highest concentrations being noted
within the highest dose cohort. The detection and replication of adenovirus in ovarian cancer
patients treated with a GMCSF-expressing Ad5/3-Δ24 was not detailed in the early phase
trial by Koski et al (25). The results of the current study were comparable to our prior early
phase trial evaluating Ad5-Δ24-RGD. In that trial, RGD-specific PCR demonstrated the
presence of study vector in the ascetic fluid of 16 of 21 treated patients (23).
Viral shedding studies in the current investigation detected elevated Ad genomic DNA
levels (>50 copies) in serum, saliva, and urine from only a few patients, mostly from the
higher dose cohorts. Wildtype adenovirus emergence after Ad5/3-Δ24 treatment was not
noted. A robust anti-viral antibody response was also noted. These findings were
comparable to that reported by Koski et al and in our prior early phase trials evaluating
RGD-modified infectivity-enhanced gene therapeutics (23–25). Preexisting neutralizing
anti-adenoviral antibody levels were noted on day 0 in the serum of patients from the low
and intermediate dose cohorts. Several studies have indicated that neutralizing antibodies, in
Kim et al. Page 8













addition to other specific and non-specific factors, can interact with adenoviral vectors and
may impair gene transfer and virus amplification in the tumor milieu (28–30). The question
remains which of these factors present in malignant ascites can affect Ad5/3 vector
infectivity in specific or nonspecific manners and, thus, limit the efficacy of oncolytic
Ad5/3-Δ24 in patients. Answering the above question requires detailed analysis of
infectivity of Ad5/3 vectors in the context of whole ascites, which was beyond the scope of
this trial.
In conclusion, this study demonstrates that a serotype-chimeric infectivity-enhanced CRAd
such as Ad5/3-Δ24 can be safely administered IP to patients with recurrent ovarian and
other selected gynecologic cancers daily for three consecutive days at dosages up to 1 × 1012
vp. Vector-related toxicities at the doses evaluated were mild, manageable, and transient.
While this was not a phase II trial designed to evaluate efficacy, SD and declines in CA-125
were noted in several patients. Evidence of gene transfer, adenoviral replication, and a
robust anti-adenoviral antibody response were noted. Efforts are underway to incorporate
novel non-invasive imaging capacity into Ad5/3-Δ24. Other preclinical studies have
demonstrated the potential synergy of Ad5/3-Δ24 in combination with conventional
chemotherapy and randomized phase II trials of chemotherapy with or without Ad5/3-Δ24
might also be justified (31). Further development and investigation of these novel CRAd
approaches in the context of ovarian cancer appears to be warranted.
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Refer to Web version on PubMed Central for supplementary material.
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- Ad5/3-Δ24 is a serotype chimeric, infectivity enhanced CRAd
- Ad5/3-Δ24 has shown oncolysis and antitumor activity in preclinical ovarian
cancer models
- Recurrent ovarian & other select gynecologic cancer patients were treated
with IP Ad5/3-Δ24
- At the doses evaluated, Ad5/3-Δ24 is a safe potential therapeutic option in
these patients
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Structure of Ad5/3-Δ24. (A) Ad5/3-Δ24 has a 24 bp deletion in the constant region 2 (CR2)
of the E1 A gene, corresponding to the region utilized for Rb protein binding. This results in
an agent that is replication-competent and oncolytic in cells defective in the Rb/p16
pathway, such as ovarian cancer cells. The fiber is modified to incorporate the serotype 3
knob, while retaining the Ad5 shaft and tail.
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Quantification of Ad5/3-Δ24 vector in ascites samples. The Ad5/3-Δ24 genome copies were
quantified (in triplicate) in each patient’s ascites specimen and normalized to the amount of
cellular DNA detected in the same sample with primers and probe for human β-actin using
duplexing quantitative PCR settings.
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Assessment of Ad5/3-Δ24 replication in ascites. The early E1A gene-specific mRNA was
quantified (in triplicate) using total mRNA isolated from each patient’s ascites specimen as a
template for reverse transcription followed by quantitative PCR. The determined copy
number of E1A mRNA was normalized to the amount of human β-actin, which was detected
in the same sample using duplexing RT-PCR settings.
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  Median 63.5
  Range 53–84
Race N (%)
  Caucasian 10 (100)
  African American 0
  Other 0
Primary cancer N (%)
  Ovarian 7 (78)
  Fallopian tube 1 (11)
  Primary peritoneal 1 (11)
Prior chemotherapy regimens N
  Median 4
  Range 1–10
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Table 3
Clinical efficacy by RECIST criteria and pre- and post-treatment CA125 levels.
Patient RECIST-defineddisease response Pre-treatment CA-125 Post-treatment CA-125
101 Stable 65.9 44.2
102 Progressive 5052.7 52,520
103* Not determined 1465.0 Not determined
201** Not applicable 60.7 Not applicable
202 Stable 62.7 20.6
203 Progressive 126.2 134.6
204 Stable 130.5 315.7
301 Stable 284.0 246.4
302 Stable 189.4 196.3
303 Stable 127.4 229.5
*
Noted as progression based on clinical deterioration
**
Did not receive study treatment due to IP catheter complication
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